REDUCE-IT
2019
Reduction of Cardiovascular Events with Icosapent Ethyl
In 8,179 statin-treated patients with high triglycerides, icosapent ethyl reduced major adverse cardiovascular events compared with placebo.
Result
Efficacy: CV death, MI, stroke, revascularisation or unstable anginaHR 0.75
Below 1 favours icosapent ethyl, above 1 favours placebo.
- Absolute difference
- 4.8 points
The absolute difference is derived from the event rates.
- Subtopic
- Triglycerides
- Design
- Double-blind RCT
- Relevance
- Important: one of several pillars.
- Source
- Bhatt DL, et al. N Engl J Med. 2019;380(1):11-22.doi 10.1056/NEJMoa1812792
Discussion & critique
The mineral-oil placebo raised LDL and CRP, so the true effect is probably smaller than the 25 % reduction. STRENGTH, with a different omega-3, was negative.